Clinical Use Of Cangrelor: Real World Data From The Swedish Coronary Angiography And Angioplasty Registry (Scaar)

Per Grimfjärd,Bo Lagerqvist,David Erlinge,Stefan James

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2018）

引用 0|浏览13

暂无评分

摘要

Cangrelor is indicated in patients undergoing PCI, where oral P2Y12-inhibition is not feasible or desirable, hence a natural choice in cardiac arrest STEMI cases. Some physicians bridge to ticagrelor, although cangrelor trials were conducted with clopidogrel. There is also off-label use in patients

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要